The effect of a series of puromycin analogues and aminoacyl chloramphenicol derivatives on poly(U,C)-directed polyphenylalanine synthesis in an Escherichia coli cell-free system was examined. A comparison between the structures and activities of the puromycin and chloramphenicol analogues was made to examine the proposal that ribosomal binding sites for both antibiotics overlap. Our results suggest that the dichloroacetamido group in the chloramphenicol molecule does not correspond to the role of the aminoacyl moieties of either puromycin or aminoacyl transfer ribonucleic acid. These results comparing the structures and activities of puromycin and chloramphenicol analogues also seem inconsistent with a common binding site for the p-substituted phenyl moieties of the two antibiotics. Previous data have indicated that both sites are mutually affected by the prior binding of either antibiotic. Although it is possible that chloramphenicol and puromycin may have overlapping bindings sites, no common structural features between the two antibiotics are supported by our data.
Chloramphenicol inhibits protein synthesis in prokaryotic cells (5) . In cell-free systems it has been demonstrated that the antibiotic binds specifically to the 50S ribosomal subunit (17) . Kinetic data (13) have shown that chloramphenicol is a competitive inhibitor of the reaction of puromycin with acetylphenylalanine transfer ribonucleic acid (tRNA) on Escherichia coli ribosomes. Synthetic derivatives of chloramphenicol, in which the dichloroacetyl group has been replaced by one of several aminoacyl groups, inhibited polyphenylalanine synthesis in a cell-free system from E. coli (2) and also inhibited the puromycin reaction (3). These observations led to the suggestion (3) that chloramphenicol and its aminoacyl derivatives inhibit protein synthesis by acting as analogues of aminoacyl-tRNA. This suggestion was extended to the proposal that the dichloroacetyl moiety of the antibiotic simulates the amino acid moiety of puromycin (Fig. 1) An alternate model was proposed to account for the mechanism of action of chloramphenicol (6) . This model suggested that the p-methoxyphenyl moiety of puromycin and the p-nitrophenyl moiety of chloramphenicol share a common binding site. These authors based their model on the idea that the nitrophenyl group is well suited to bind to a proposed hydrophobic site on the peptidyl transferase acceptor site, which is involved in the binding of the aromatic aminoacyl R groups of Phe-and Tyr-tRNA and also of the O-methyltyrosyl residue of puromycin. In this communication we explore the possible overlap of binding sites for the two antibiotics in an E. coli cell-free system by examining the relative contributions of various aminoacyl moieties of chloramphenicol and puromycin analogues.
MATERIALS AND METHODS
Puromycin dihydrochloride and puromycin aminonucleoside (PAN) were obtained from Nutritional Biochemicals Co. Chloramphenicol was obtained from Parke, Davis and Co. Assay conditions for inhibition of poly(U,C)-directed polyphenylalanine formation were previously described (19) . the carbocyclic aminonucleoside (-)-2a-amino-5#-(6-dimethylamino-9-purinyl)cyclopentan-la-ol ( 19) or chloramphenicol base with the corresponding N-substituted amino acids (or carboxylic acid) by the dicyclohexylcarbodiimide-N-hydroxy-succinimide method (4) . The N-benzyloxy carbonyl-blocking group was used in the preparation of compounds 1 through 4 and 6 and was removed by hydrogenolysis (1 through 4) or by HBr in acetic acid (compound 6) . The N-phthalimido-blocking group was used to prepare compounds 7 
RESULTS AND DISCUSSION
Previous studies have firmly established that the carbocyclic puromycin analogue (Fig. 2 ) has a mechanism of action similar to that of puromycin (14, 18, 19) . The effect of the carbocyclic analogues of puromycin on the rate of poly(U,C)-directed polyphenylalanine formation in an E. coli cell-free system with washed ribosomes is shown in Table 1 . Corresponding aminoacyl derivatives of chloramphenicol are listed in Table 2 .
Proposal A (Fig. 1 ) predicts an overlap in the aminoacyl binding sites for chloramphenicol and puromycin. Thus, modification in the aminoacyl moiety (R) would be expected to exhibit the same effect on activity in both sets of analogues. In addition, proposal A predicts that the replacement of -CH(NH2)R of puromycin with -CHCl2 would result in a puromycin derivative with considerable activity since both moieties are binding to the same site. However, we have prepared dichloroacetamidopuromycin aminonucleoside and found it to exhibit only 11% inhibition of polyphenylalanine formation at 10 times the concentration required for 100% inhibition by puromycin. In addition, a comparison of the aminoacyl derivatives in Table 1 with the corresponding aminoacyl derivatives in Table 2 rules out the possibility of such a simple overlap in binding sites for the aminoacyl moi- a All compounds were assayed at 10-4 M. Assay conditions were as described in reference 19. eties. For example, the relative activities of the D-and L-Phe analogues revealed a high degree of specificity for the L-configuration in the puromycin analogues and no detectable specificity with chloramphenicol compounds. Removal of the p-OMe group from the aromatic moieties did not alter the activity of the puromycin analogues (Table 1) , whereas a 2.3-fold decrease in activity was noted in the chloramphenicol derivatives ( Table 2 ). The decreased activity noted for the L-Leu puromycin analogue (Table  1) is consistent with previous observations that replacement of the aromatic amino acid with a nonaromatic moiety greatly decreases activity (9, 16, 18) . In contrast, however, the L-Phe and L-Leu chloramphenicol analogues (Table 2 ) exhibited little or no difference in effects on protein synthesis. It is also interesting to note that the glycine analogue is one of the most active aminoacyl chloramphenicols. Another striking difference between the two aminoacyl binding regions is illustrated by the phenylpropionyl derivatives. Replacement of the amino acid with phenylpropionyl completely abolished activity in the puromycin series while it actually increased the inhibitory activity of the chloramphenicol compounds. A similar effect was observed with the p-NO2-Phe analogues.
Thus, the nitro group abolished the activity in the puromycin series, whereas the corresponding chloramphenicols were relatively active.
(Since the L-and D-p-nitro-Phe chloramphenicols exhibited relatively similar activities, no attempt was made to identify absolute configurations.) Proposal B suggests a common binding site for the nitrophenyl group of chloramphenicol and the methoxyphenyl of puromycin (6) . This model predicts that a nitrophenylalanyl derivative of puromycin should exhibit a high degree of activity. However, it has been pointed out above that the p-NO2-Phe derivative (Table 1) was inactive. This observation suggests that the nitrophenyl group cannot bind to the same ribosomal site normally occupied by the aminoacyl moiety of puromycin. The DL-threo-N-dichloroacetyl-p-NO2-phenylserine analogue 9 (Table 1) represents a combined chloramphenicol-puromycin analogue (Fig. 2) designed to test proposal B. This compound exhibited only slight activity inconsistent with proposal B. Removal of both the -NO2 and dichloroacetate groups restored activity as seen by the DL-threo-phenylserine analogue in Table 1 . This is consistent with the necessity of the phenyl ring and free amino group for puromycin activity. Dichloroacetylation of the amine yielded the much less active DL-threo-N-dichloroacetylphenylserine analogue (Table 1) .
The present results suggest that the -CHCl2 group of the chloramphenicol molecule does not correspond to the role of the aminoacyl moieties of puromycin or aminoacyl-tRNA. These results comparing the structures and activities of puromycin and chloramphenicol analogues also seem inconsistent with a common binding site for the p-substituted phenyl moieties of the two antibiotics.
A number of independent results have suggested mutual interactions of chloramphenicol and puromycin with ribosomes. Reconstitution experiments with ribosomal proteins demonstrated that the ribosome contains a binding site for chloramphenicol that is located at the acceptor site of the peptidyl transferase center (11) . Equilibrium dialysis studies also indicate that puromycin can inhibit chloramphenicol binding to ribosomes (8, 11) . Studies with aminoacyl oligonucleotides have demonstrated that both antibiotics inhibit the binding of C-A-C-C-A(Phe) to ribosomes (12) . Structural similarities between puromycin and the aminoacyl-adenyl terminus of aminoacyl-tRNA suggested the generally accepted postulate that puromycin binds to the acceptor site that is normally occupied by aminoacyl-tRNA (20) . Since both antibiotics appear to interact with the acceptor site, it was tempting to speculate about common structural features determining their binding to the acceptor site. However, such a simple explanation does not appear consistent with the present results. Although it is possible that chloramphenicol and puromycin may have overlapping binding sites, no cotnmon structural features are supported by our data.
Our results, therefore, seem paradoxical since, although puromycin and chloramphenicol seem to interact at similar sites, as discussed above, our results with the structural modifications do not lend support to this concept. Perhaps the present results are consistent with an allosteric mechanism of inhibition by chloramphenicol. Alternately, the ribosome may be a dynamic rather than a static structure (S. Pestka, Prog. Nucl. Acid Res. Mol. Biol., in press) and able to interact with both antibiotics differentially at the same or adjacent sites at different stages of the ribosome epicycle.
